Education
About Us
Working with TipRanks
Follow Us
NeonMind Biosciences Inc (TSE:LCR)
:LCR
LCR Stock Chart & Stats
C$0.04
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.04
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.08
Previous CloseN/A
Volume126.00K
Average Volume (3M)290.69K
Market Cap
C$3.24M
Enterprise ValueC$3.04M
Total Cash (Recent Filing)C$206.03K
Total Debt (Recent Filing)C$1.14M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding92,499,870
10 Day Avg. Volume583,757
30 Day Avg. Volume290,695
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reduced Cash Burn (year-over-year)A material reduction in operating cash outflow versus the prior year indicates management has begun to slow the rate of cash consumption. That durable trend lengthens runway, lowers near-term financing urgency, and improves the company's ability to execute next-stage R&D or commercialization plans without immediate large capital raises.
Shrinking Historical LossesReported losses have narrowed from prior peak years, suggesting improving cost control or lower extraordinary expenses. A persistent decline in absolute losses, if sustained, reduces cumulative deficit growth, eases pressure on working capital, and increases the odds management can reach break-even once revenue begins.
Lean Operating Structure (small Team)A compact employee base implies lower fixed overhead and potentially greater capital efficiency for a pre-revenue developer. Over the medium term this lean structure can preserve cash, enable nimble product pivots, and allow incremental scaling tied to milestone-driven funding or revenue inflection without a large step-up in fixed costs.
Bears Say
Pre-revenue Business ModelNo trailing revenue means the company has not demonstrated commercial product-market fit; operating losses and R&D spend remain dependent on future financing. This structural absence of revenue makes cash runway, product regulatory success, or partner deals the primary value drivers and increases execution risk over the medium term.
Negative Shareholders' EquityNegative equity and debt roughly matching or exceeding assets signal a strained capital structure and elevated solvency risk. This limits access to traditional financing, increases the likelihood of dilutive capital raises, and constrains strategic flexibility for investments or partnerships over the coming months.
Persistently Negative Cash GenerationSustained negative operating and free cash flow indicate ongoing cash burn that must be met with external funding. Even with year-over-year improvement, nearly -1.0M TTM outflow is large relative to the balance sheet and creates recurring financing need, raising dilution and execution risk until positive cash generation is achieved.
NeonMind Biosciences Inc News
LCR FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was C$0.01 and its highest was C$0.08 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is C$3.24M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Aug 05, 2026 which is in 137 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
NeonMind Biosciences Inc released its earnings results on Mar 03, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 92,499,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
NeonMind Biosciences Inc reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:LCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. engages in the acquisition, exploration, and development of mineral properties and renewable energy projects. It has option to acquire a 100% interest in the Alkali Flat lithium brine project situated in Lordsburg, New Mexico, the United States. The company is based in West Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---